GRANULES Granules India Q2 FY27 results (Jul–Sep 2026) and concall
Granules India presented a strategic update, 'The Now & The Next,' outlining its transformation into Granules 2.0. The company highlighted its return to growth in FY26, driven by investments in manufacturing, R&D, and new capabilities. Key growth engines include controlled substances, complex generics, oncology, and peptide CDMO. Financial performance showed significant margin expansion and strong cash generation, positioning the company for future organic and inorganic growth, supported by a planned ₹2,000 crore capex over the next 3-4 years.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed before this quarter
Q1 FY27: revenue down 1.0%, net profit up 4.3% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 568 | 842 | 768 | 810 | 892 +57% | 895 +6% | 877 +14% | 802 −1% |
| EBITDA | 103 | 168 | 117 | 144 | 211 +105% | 194 +15% | 175 +50% | 131 −9% |
| Net profit | 41 | 90 | 94 | 69 | 121 +195% | 112 +24% | 99 +5% | 72 +4% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
